Update on the molecular pathogenesis and clinical treatment of Mantle Cell Lymphoma (MCL): minutes of the 9th European MCL Network conference

References

• Martin P, Chadburn A, Christos P, et al Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009;27:1209–1213.
   PubMed Web of Science ®Google Scholar
• Dreyling M, Hiddemann W. Current treatment standards and emerging strategies in mantle cell lymphoma. American Society of Hematology Education Program Book. Hematology 2009:542–554.
   PubMedGoogle Scholar
• Weigert O, Unterhalt M, Hiddemann W, Dreyling M. Mantle cell lymphoma: state-of-the-art management and future perspective. Leuk Lymphoma 2009;50:1937–1950.
   PubMed Web of Science ®Google Scholar
• Fernàndez V, Salamero O, Jares P, et al Hypermutation of immunoglobulin genes and a low genomic instability define a new subtype of mantle cell lymphoma with very indolent outcome. XIV Meeting of the European Association for Haematopathology, Bordeaux, 2008. J Hematopathol 2008;1:161–256 (LS 18).
   PubMedGoogle Scholar
• Fernàndez V, Salamero O, Espinet B, et al Indolent mantle cell lymphoma identified by genomic and gene expression profiling. Cancer Res 2010;70:1408–1418.
   PubMed Web of Science ®Google Scholar
• Mozos A, Royo C, Hartmann E, et al SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 2009;94:1555–1562.
   PubMed Web of Science ®Google Scholar
• Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007;7:750–762.
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Wiestner A, et al The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003;3:185–197.
   PubMed Web of Science ®Google Scholar
• Fu K, Weisenburger DD, Greiner TC, et al Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005;106:4315–4321.
   PubMed Web of Science ®Google Scholar
• Lenz, G, Wright GW, Emre NC, et al Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA 2008;105:13520–13525.
   PubMed Web of Science ®Google Scholar
• Stöcklein H, Smardova J, Macak J, et al Detailed mapping of chromosome 17p deletions reveals HIC1 as a novel tumor suppressor gene candidate telomeric to TP53 in diffuse large B-cell lymphoma. Oncogene 2008;27:2613–2625.
   PubMed Web of Science ®Google Scholar
• Stöcklein H, Hutter G, Kalla J, et al Genomic deletion and promotion methylation status of Hypermethylated in Cancer 1 (HIC1) in mantle cell lymphoma. J Hematopathol 2008;1:85–95.
   PubMedGoogle Scholar
• Fleuriel C, Touka M, Boulay G, et al HIC1 (Hypermethylated in Cancer 1) epigenetic silencing in tumors. Int J Biochem Cell Biol 2009;41:26–33.
   PubMed Web of Science ®Google Scholar
• Britschgi C, Jenal M, Rizzi M, et al HIC1 tumour suppressor gene is suppressed in acute myeloid leukaemia and induced during granulocytic differentiation. Br J Haematol 2008;141:179–187.
   PubMed Web of Science ®Google Scholar
• Dehennaut V, Leprince D. Implication of HIC1 (Hypermethylated In Cancer 1) in the DNA damage response. Bull Cancer 2009;96:E66–E72.
   PubMed Web of Science ®Google Scholar
• Hoster E, Unterhalt M, Wörmann B, et al on behalf of the German Low-Grade Lymphoma Study Group (GLSG) and the European MCL Network. The addition of rituximab to first-line chemotherapy (R-CHOP) results in superior response rates, time to treatment failure and response duration in patients with advanced stage mantle cell lymphoma – long-term results of a GLSG trial. Blood 2008;112(Number 11): 1048 (Abstract 3049).
   Google Scholar
• Bireland ML, Monroe JG. Biochemistry of antigen receptor signaling in mature and developing B lymphocytes. Crit Rev Immunol 1997;17:353–385.
   PubMed Web of Science ®Google Scholar
• Su TT, Guo B, Rawlings DJ. Emerging roles for PKC isoforms in immune cell function. Mol Interv 2002;2:141–144.
   PubMedGoogle Scholar
• Decouvelaere AV, Morschhauser F, Buob D, et al Heterogeneity of protein kinase C beta(2) expression in lymphoid malignancies. Histopathology 2007;50:561–566.
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Seymour JF, Kluin-Nelemans HC, et al A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma. Ann Oncol 2008;19:247–253.
   PubMed Web of Science ®Google Scholar
• Martin-Subero JI, Ammerpohl O, Bibikova M, et al A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms. PLoS One 2009;4:e6986.
   PubMed Web of Science ®Google Scholar
• Rubio-Moscardo F, Climent J, Siebert R, et al Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood 2005;105:4445–4454.
   PubMed Web of Science ®Google Scholar
• Salaverria I, Zettl A, Bea S, et al Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol 2007;25:1216–1222.
   PubMed Web of Science ®Google Scholar
• Pott C, Hoster E, Delfau-Larue MH, et al Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 2010;115:3215–3223.
   PubMed Web of Science ®Google Scholar
• van der Velden VHJ, Cazzaniga G, Schrauder A, et al Analysis of minimal residual disease by IG/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007;21:604–611.
   PubMed Web of Science ®Google Scholar
• Hoster E, Dreyling M, Klapper W, et al A new prognostic index (MIPI) for patients with advanced stage mantle cell lymphoma. Blood 2008;111:558–565.
   PubMed Web of Science ®Google Scholar
• Salek D, Vasova I, Pytlik R, et al Mantle Cell Lymphoma International Prognostic Score is valid and confirmed in unselected cohort of patients treated in rituximab era. Blood 2008;112(Suppl. 1):1283 (Abstract 3745).
   Google Scholar
• Dreyling M, Hoster E, Hermine O, et al European Mantle Cell Lymphoma Network: an update on current first line trials. Ann Oncol 2008;19(Suppl. 4): Abstract 300.
   Google Scholar
• Zinzani PL, Witzig TE, Vose JM. Confirmation of the efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: results of an international study (NHL-003). Blood 2008;112(Suppl. 1):103 (Abstract 262).
   Google Scholar
• Wiernik PH, Lossos IS, Tuscano JM, et al Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4952–4957.
   PubMed Web of Science ®Google Scholar
• Rummel M, von Gruenhagen U, Niederle N. Bendamustine plus rituximab versus CHOP plus rituximab in the first-line treatment of patients with follicular, indolent and mantle cell lymphomas: results of a randomized phase III study of the study group indolent lymphomas (StiL). Blood 2008;112(Suppl. 1):900 (Abstract 2596).
   Google Scholar
• Robinson KS, Williams ME, van der Yagt RH, et al Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4473–4479.
   PubMed Web of Science ®Google Scholar
• Jurczak W, Szymczyk M, Giza A, et al Overall survival (OS) benefit of rituximab based immunochemotherapy followed by post-induction treatment in mantle cell lymphoma (MCL): a retrospective analysis of 279 patients treated by Polish Lymphoma Research Group (PLRG) centers. Blood 2009;114(Suppl. 1):678 (Abstract 1702).
   Google Scholar
• Jurczak W, Giza A, Krochmalczyk D, et al Radioimmunotherapy (RIT) as an alternative consolidation of MCL patients not illegible for transplant protocols – final analysis of multicenter Polish Lymphoma Research Group (PLRG) trial with 90Y-Zevalin (90Y-ibritumomab tiuxetan). Ann Oncol 2008;19: Abstract 173.
   Web of Science ®Google Scholar
• Jurczak W, Skotnicki AB, Deptala A, et al Consolidation with radioimmunotherapy may prolong survival in first remission of mantle cell lymphoma patients uneligible for stem cell transplantation, an analysis of the International RIT-Network. Blood 2009;114(Suppl. 1):1442 (Abstract 3746).
   Google Scholar
• Klapper W, Hoster E, Determann O, et al Ki-67 as a prognostic marker in mantle cell lymphoma – consensus guidelines of the pathology panel of the European MCL Network. J Hematopathol 2009 Jun 16. [Epub ahead of print].
   Google Scholar